Impact of Socioeconomic Status on the Initiation of SGLT2 Inhibitors in Heart Failure Patients

Overview

This study investigates the influence of socioeconomic factors on the initiation of SGLT2 inhibitors in heart failure patients. It highlights disparities in prescription patterns based on socioeconomic status.

Background

Socioeconomic factors are known to impact cardiovascular health and outcomes, including heart failure. Despite the benefits of SGLT2 inhibitors in managing heart failure, disparities in their prescription based on socioeconomic status have not been thoroughly examined.

Data Highlights

No numerical data was provided in the source material.

Key Findings

• Socioeconomic deprivation influences cardiovascular risk from an early age.
• Higher income correlates with better survival rates and shorter hospital stays in myocardial infarction patients.
• Previous studies indicate that low socioeconomic status is linked to lower prescription rates of guideline-directed therapies.
• Disparities in SGLT2 inhibitor usage have been observed.
• Real-world prescription patterns of SGLT2 inhibitors have not been extensively studied in relation to socioeconomic factors.

Clinical Implications

Healthcare providers should be aware of the socioeconomic factors that may influence the initiation of SGLT2 inhibitors in heart failure patients.

Conclusion

The study highlights the need to explore socioeconomic influences on medication initiation in heart failure management.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Drugs - Real World Outcomes — Association of Sodium-Glucose Cotransporter-2 Inhibitors with Decreased Heart Failure Hospitalization Risk in Patients with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: Insights from a Diverse Urban Cohort Study
3. Frontiers in Cardiovascular Medicine — Efficacy of SGLT2 inhibitors in Patients Recently Hospitalized for Heart Failure: An Exploratory Prespecified Pooled Analysis of the DELIVER and EMPEROR-Preserved Trials
4. Frontiers in Cardiovascular Medicine — Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity score-matched retrospective cohort study
5. Frontiers in Cardiovascular Medicine — Expanding the scope of SGLT inhibitors in underrepresented cardiac populations: from pathophysiology to clinical evidence
6. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
7. Effects of SGLT2 Inhibitors on Clinical Outcomes, Symptoms, Functional Capacity, and Cardiac Remodeling in Heart Failure: A Comprehensive Systematic Review and Multidomain Meta-Analysis of Randomized Trials
8. Circulation: Cardiovascular Quality and Outcomes